Research paperComparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia
References (18)
- et al.
Treatment of type III hyperlipoproteinemia with four different treatment regimens
Atherosclerosis
(1984) - et al.
Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease
Am. Heart J.
(1988) - et al.
The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia
Metabolism
(1990) - et al.
Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia
Metabolism
(1985) - et al.
Effect of fenofibrate treatment on type III hyperlipoproteinemia
Am. J. Med.
(1987) - et al.
Influence of bezafibrate and colestipol on LDL cholesterol, LDL apolipoprotein B and HDL cholesterol in hyperlipoproteinemia
Atherosclerosis
(1987) - et al.
Mode of action of lipid lowering agents clofibrate and BM15075 on cholesterol biosynthesis in rat liver
Atherosclerosis
(1978) - et al.
Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats
Atherosclerosis
(1983) - et al.
Type III hyperlipoproteinemia.
Cited by (20)
Enhanced antihyperlipidemic potential of gemfibrozil under co-administration with piperine
2021, Current Research in Pharmacology and Drug DiscoveryCitation Excerpt :The body weights were recorded before and after the experiments to ensure the induction of hypercholesterolemia. The experiments were conducted for about 4 weeks and the groups received the following drug treatments: group 1 (NRML) served as the normal control; group 2 (HFF) served as the disease control and did not receive any drug treatment; group 3 (GEM) served as the drug control and received gemfibrozil alone at a dose of 20 mg/kg/day; group 4 (PIP) received piperine alone at a dose of 5 mg/kg/day; group 5 (GEM-PIP-5) received gemfibrozil and piperine at doses of 20 mg/kg/day and 5 mg/kg/day, respectively; group 6 (GEM-PIP-10) received gemfibrozil and piperine at doses of 20 mg/kg/day and 10 mg/kg/day, respectively; and group 7 (GEM-PIP-20) received gemfibrozil and piperine at doses of 20 mg/kg/day and 20 mg/kg/day, respectively [10]. The drugs were administered via oral garage in corn oil.
Toxicological relevance of emerging contaminants for drinking water quality
2010, Water ResearchFibrates
2009, Clinical Lipidology: A Companion to Braunwald's Heart DiseaseFibrates
2008, Clinical Lipidology: A Companion to Braunwald's Heart Disease Expert Consult: Online and PrintChanges in isoprenoid lipid synthesis by gemfibrozil and clofibric acid in rat hepatocytes
2000, Biochemical PharmacologyPeroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis
1998, Journal of Biological Chemistry
- †
Present address: Department of Cardiology A, Aarhus Amtssygehus, Tage-Hansens Gade 2, DK-5000 Odense C, Denmark.